Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 54,651 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 54,651 shares of the biopharmaceutical company's stock, valued at approximately $1,601,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.09% of Agios Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in AGIO. GF Fund Management CO. LTD. acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $39,000. CWM LLC grew its holdings in shares of Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 996 shares during the period. Sterling Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares during the period. Summit Investment Advisors Inc. increased its stake in Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after purchasing an additional 394 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Agios Pharmaceuticals by 9,296.6% during the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock worth $240,000 after purchasing an additional 8,088 shares during the last quarter.

Agios Pharmaceuticals Trading Down 6.0%

Shares of NASDAQ AGIO traded down $2.22 during midday trading on Friday, reaching $35.00. 2,351,119 shares of the stock were exchanged, compared to its average volume of 723,031. The stock has a 50 day moving average price of $35.69 and a 200-day moving average price of $32.57. The company has a market capitalization of $2.03 billion, a P/E ratio of 3.18 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.39% and a net margin of 1,590.42%. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AGIO. Scotiabank lowered their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Bank of America lowered their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Finally, Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $56.33.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 1,780 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $59,701.20. Following the completion of the sale, the chief financial officer owned 30,049 shares in the company, valued at $1,007,843.46. The trade was a 5.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sarah Gheuens sold 11,914 shares of the stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total transaction of $452,612.86. Following the transaction, the insider owned 61,271 shares in the company, valued at approximately $2,327,685.29. The trade was a 16.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,363 shares of company stock valued at $1,619,654. 4.30% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.